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Available online 11 October 2016Background: Initiation of antiretroviral therapy (ART) and subsequent virologic suppression reduces immune ac-
tivation and systemic inﬂammation.
Methods:We examined longitudinal changes in biomarkers of monocyte activation (sCD14, sCD163), and sys-
temic (IL-6, hsCRP, sTNFR-I and D-dimer) and vascular (Lp-PLA2) inﬂammation in a subgroup (N = 100 per
arm) of participants enrolled in a randomized, placebo-controlled trial comparing elvitegravir/cobicistat/
emtricitabine/tenofovir alafenamide (E/C/F/TAF; TAF) to E/C/F/tenofovir disoproxil fumarate (E/C/F/TDF; TDF)
in treatment-naïve adults.
Results: For 194 participants (TAF, 98; TDF, 96), baseline levels of biomarkers did not differ by treatment arm;
there were no differences in biomarker values between groups at weeks 12, 24, or 48 (p N 0.05), except IL-6 at
week 12 (p = 0.012). Among all participants (combining groups), there were statistically signiﬁcant declines
from baseline observed for D-dimer, sCD163, and sTNFR-1 by week 12 and IL-6 by week 24. The proportion of
participants with Lp-LA2 levels b 200 ng per mL (p= 0.250) or hsCRP levels b3000 mg per L (p= 0.586) was
unchanged through week 48.
Conclusions:We observed equivalent declines in biomarkers of monocyte activation and systemic inﬂammation
in treatment-naïve adults treatedwith TAF or TDF for 48weeks, suggesting that TAF and TDF have equivalent im-
pact on immune activation and inﬂammation.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Treatment with combination antiretroviral therapy (ART) has in-
creased the lifespans of persons infected with the human immunodeﬁ-
ciency virus (HIV) (Antiretroviral Therapy Cohort, C, 2008; Mills et al.,
2011); however, immune activation and chronic inﬂammation have
been shown to persist in spite of suppressed viral replication
(Funderburg, 2014; Deeks et al., 2013; Hunt et al., 2014; Lederman et
al., 2011). Several soluble markers of immune activation and inﬂamma-
tion, including interleukin-6 (IL-6) (Hunt et al., 2014; Sandler et al.,
2011; Longenecker et al., 2014), high-sensitivity C-reactive protein
(hsCRP), and tumor necrosis factor α receptor I (sTNFR-I) (Hunt et al.,
2014; Tenorio et al., 2015; Kalayjian et al., 2010) are associated withst 10th Avenue, Columbus, OH
Funderburg).
. This is an open access article underall-cause mortality (Kalayjian et al., 2010 and Kuller et al., 2008) and
deaths related to cardiovascular disease (CVD) (Duprez et al., 2012) in
HIV-infected individuals (Tenorio et al., 2015). Soluble markers of
monocyte and macrophage activation (sCD14 or sCD163) are also asso-
ciated with mortality (Hunt et al., 2014 and Sandler et al., 2011), coro-
nary calcium levels (Longenecker et al., 2014), and unstable coronary
plaques (Burdo et al., 2011) in this population. Comparing the levels
of immune activation and inﬂammation after the initiation of different
ART regimens can provide additional information about the effective-
ness of the regimens beyond virologic suppression.
Antiretroviral therapy regimensmost commonly include two nucle-
oside reverse transcription inhibitors (NRTIs) and a third drug from a
different class. Tenofovir disoproxil fumarate (TDF) (National Center
for Biotechnology Information, n.d.-a, CID = 6,398,764) is a potent
and well-tolerated NRTI recommended by all major treatment guide-
lines (Panel on Antiretroviral Guidelines for Adults and Adolescents,
2015; Huldrych et al., 2014; European AIDS Clinical Society, 2015), butthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
322 N.T. Funderburg et al. / EBioMedicine 13 (2016) 321–327is also associated with greater nephrotoxicity (Hall et al., 2011; Gupta,
2008; Post et al., 2010) and bone mineral density loss (Stellbrink et al.,
2010; Schafer et al., 2013;McComsey et al., 2011) than other nucleoside
or nucleotide reverse transcriptase inhibitors. TDF is a prodrug that is
metabolized to tenofovir (TFV), which is diphosphorylated intracellu-
larly to its active metabolite, TFV diphosphate (TFV-DP). Higher circu-
lating plasma TFV levels have been associated with the renal and bone
effects of TDF (Van Rompay et al., 2008).
Tenofovir alafenamide (TAF) (National Center for Biotechnology
Information, n.d.-b, CID = 9,574,768) is a prodrug of TFV that is more
stable in plasma, allowing for a ten-fold reduction in dose and resulting
in a 91% reduction in plasma TFVwhile achieving a four-fold increase in
intracellular levels of TFV-DP (Sax et al., 2015).
A single tablet co-formulation of elvitegravir/cobicistat/emtricitabine/
tenofovir alafenamide (E/C/F/TAF) demonstrated high efﬁcacy and im-
proved renal andbone safety acrossmultiple populations in Phase 3 trials:
treatment-naïve adults and adolescents, and in adults switching from
TDF-based regimens with or without chronic kidney disease (Sax et al.,
2015; Mills et al., 2011; Pozniak et al., 2016; Gaur et al., 2014). It is ap-
proved by the U.S. Food and Drug Administration, 2014 and European
Medicines Agency for treatment of naïve and stably suppressed patients
age 12 and older and is a recommended initial regimen in U.S. Depart-
ment of Health and Human Services guidelines (U.S. Department of
Health and Human Services, 2015).
Here, in this randomized, selected substudy of a treatment naïve
adult trial (GS-US-292-0104 [Sax et al., 2015]), we compare the ef-
fects of E/C/F/TAF versus E/C/F/TDF, referred to as the TAF and TDF
groups, respectively, on biomarkers of systemic (IL-6, hsCRP,
sTNFR-I) and vascular (lipoprotein-associated phospholipase A2
[Lp-PLA2]) inﬂammation, coagulation (D-dimer), and soluble
markers of myeloid cell activation (sCD14 and sCD163) from base-
line through 48 weeks of treatment. In this exploratory analysis,
we hypothesized that changes in markers of immune activation
would be similar between the groups, as participants in both arms
were treated with a potent, integrase-based regimen, and because
there were no differences in plasma virologic suppression between
the TAF and TDF arms in the parent study. Several potential contrib-
utors to chronic immune activation in ART-treated HIV infection
have been identiﬁed, however, including: microbial translocation
and dysbiosis, co-infections, elevations in pro-inﬂammatory lipid
levels, and low level HIV-1 replication in tissue sites that may not
be captured by measurement of HIV-1 levels in plasma (Lederman
et al., 2013). The differential effects of TDF and TAF on these other
drivers of immune activation are also currently not known. As new
ART compounds are identiﬁed, their effects on indices of immune ac-
tivation and inﬂammation that have been linked to morbidity and
mortality (Funderburg, 2014; Lederman et al., 2013) will need to
be assessed.2. Materials and Methods
2.1. Study Design
This is a substudy (n=200) of a randomized, double-blinded, ac-
tive-controlled, non-inferiority trial of treatment-naïve adults initi-
ating TAF vs TDF (GS-US-292-0104, N = 867, ClinicalTrials.gov
number NCT01780506) (Sax et al., 2015). We randomly selected
100 participants from each arm, stratifying by baseline CD4+ and
HIV-1 RNA, age, sex, and geography, and excluded participants
with known cardiovascular disease or statin use at baseline or during
study. This study was conducted in accordance with the Declaration
of Helsinki. Central or site-speciﬁc institutional review boards or
ethics committees reviewed and approved the protocol. All
participants provided consent for use of storage samples for future
research purposes.2.2. Measurement of Plasma Biomarkers
Plasma levels of immune activation and inﬂammation were mea-
sured in the Funderburg Lab (Ohio State University, Columbus, OH)
using commercially available enzyme-linked immunosorbent assay
(ELISA) kits. Plasma samples were thawed at 4 °C overnight and
analyzed in batch. The concentrations of sCD14, IL-6, hsCRP,
sCD163, and TNFR-I (R&D Systems; Minneapolis MN), D-dimer
(Asserachrom D-DI immunoassay, Diagnostica Stago, Asnieres
France), and Lp-PLA2 (PLAC test ELISA kit, Diadexus Inc.; San
Francisco CA) were measured using protocols provided by the
manufacturers. The inter- and intra-assay variability among these
assays ranged between 3.9 and 11.2% and 3.4–9.8%, respectively.
2.3. Statistical Analyses
We summarized baseline levels and percent changes from base-
line at post-baseline visits, compared between treatment groups
usingWilcoxon Rank Sum, and tested percent changes from baseline
at post-baseline visits within treatment groups and overall using
Wilcoxon Signed Rank tests. We performed an additional compari-
son between the two baseline HIV-1 RNA categories by Wilcoxon
rank sum test. For the two markers (Lp-PLA2 and hsCRP) with ac-
cepted clinical cutoffs associated with increased cardiovascular risk
(b200 or ≥200 ng per mL for Lp-PLA2, (Packard et al., 2000; Koenig,
2006; U.S. Food and Drug Administration, 2014) b3000 or ≥
3000 ng per mL for hsCRP (Ridker, 2016)), we used McNemar's test
to compare if the proportion of participants within each paired cate-
gorical data was different at baseline and at post-baseline visits. We
also stratiﬁed by baseline HIV-1 RNA category (≤100,000 vs N
100,000 copies per mL) to test for differences in the percent changes
in any biomarkers between treatment arms. To test equivalence be-
tween arms in terms of biomarker change from baseline to week
48, two one-sided tests (TOST) were used, and 90% conﬁdence inter-
vals (CI) were constructed for ratios of biomarker percent change be-
tween the two arms, with baseline clinical characteristics,
demographics, and other biomarkers at baseline adjusted or not ad-
justed. To account for correlations among biomarkers, multivariate
multiple regression (MMR) was ﬁtted for biomarker percent change
from baseline to week 48 against treatment arms, with baseline
clinical characteristics, demographics, and baseline biomarkers
adjusted. All seven biomarkers collectively were then compared
between arms using Wilks's lambda test. The machine learning
algorithm Random Forest was used to assess biomarkers' ability to
differentiate treatment arms using a receiver operating characteris-
tic (ROC) curve and variable importance analysis.
3. Results
Of the 200 participants selected for this substudy, 194 had
evaluable samples (TAF: n=98; TDF: n=96). Baseline demograph-
ic and clinical information is provided in Table 1. Median baseline
age, CD4+ cell count, and viral load for the subpopulation were sim-
ilar to those for the parent study. A total of 19% (37 of 194 partici-
pants) were women, 44% (85 of 194) were non-white, and 28% (55
of 194) were smokers; the median age was 33 years. The only
signiﬁcant differences between groups were in body mass index
(median, TAF: 24 kg per m2, TDF: 25 kg per m2; p = 0.043) and
percentage of smokers (TAF: 35% [34 of 98], TDF: 22% [21 of 96];
p = 0.043). Participants had a median CD4+ cell count of 405 cells
per μL and a median level of viremia of 4.7 log10 copies per mL; 25%
had viral load N100,000 copies per mL.
Mean increases in CD4 cell counts were similar between groups at
week 48 (TAF: 240 cells per μL, TDF: 238 cells per μL; p = 0.98).
Consistent with the parent study, we found similar declines in
viremia between arms. A greater proportion of those receiving the
Table 1
Demographics and baseline clinical characteristics.
TAF (n =
98)
TDF (n =
96)
Total (n =
194)
p-Value
Age, median (IQR) 34 (26, 41) 32 (27, 41) 33 (26, 41) 0.95
Female, n (%) 21 (21) 16 (17) 37 (19) 0.40
Black, n (%) 19 (19) 13 (14) 32 (16) 0.27
BMI, median (IQR) 24 (22, 27) 25 (22, 29) 24 (22, 28) 0.043
US region, n (%) 48 (49) 54 (56) 102 (53) 0.31
CD4 count, cells per μL, median
(IQR)
402 (254,
591)
405 (297,
521)
405 (274,
560)
0.82
CD4 b 200 cells per μL, n (%) 16 (16) 13 (14) 29 (15)
HIV RNA, log10 copies per mL,
median (IQR)
4.7 (4.1,
5.0)
4.7 (4.3,
4.9)
4.7 (4.2,
5.0)
0.78
HIV RNA b100,000 copies per
mL, n (%)
72 (74) 74 (77) 146 (75) 0.27
Smoker, n (%) 34 (35) 21 (22) 55 (28) 0.043
Total cholesterol, mg per dL,
median (IQR)
163 (146,
184)
167
(149,195)
166 (147,
187)
0.17
LDL, mg per dL, median (IQR) 106
(88,122)
109 (91,
129)
107 (89,
127)
0.20
HDL, mg per dL, median (IQR) 46 (35, 54) 46 (37, 54) 46 (36, 54) 0.67
Triglycerides, mg per dL,
median (IQR)
106 (77,
153)
108 (82,
137)
107 (80,
145)
0.70
TC:HDL ratio, median (IQR) 3.8 (3.1,
4.3)
3.6 (3.2,
4.4)
3.6 (3.2,
4.3)
0.97
eGFR by Cockcroft-Gault,
median (IQR)
120 (103,
135)
116 (102,
139)
118 (103,
137)
0.95
Hemoglobin, g per dL, median
(IQR)
14.3 (13.2,
15.3)
14.6 (13.5,
15.2)
14.4 (13.2,
15.2)
0.39
Diabetes mellitus, n (%) 3 (3) 3 (3) 6 (3) 0.98
Hypertension, n (%) 10 (10) 16 (17) 26 (13) 0.19
Hyperlipidemia, n (%) 2 (2) 4 (4) 6 (3) 0.39
Bold lettering denotes a p-value less than 0.05.
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mL of HIV-1 RNA, Missing = Failure Analysis) at week 2 compared
with those receiving TDF (34% [33 of 98] versus 23% [22 of 96];
p = 0.046), but this difference was not maintained through 48
weeks. From week 16 through week 48, N95% of participants in
both arms had undetectable levels of HIV-1. There were increases
from baseline at week 48 in total cholesterol (TC) (TAF: 20 mg per
dL; TDF: 12 mg per dL; p = 0.004), low density lipoprotein (LDL)
(TAF: 12 mg per dL; TDF: 3 mg per dL; p= 0.006), high density lipo-
protein (HDL) (TAF: 5 mg per dL; TDF: 3 mg per dL; p = 0.045),
TC:HDL ratio (TAF: 0.1, TDF: 0.2; p = 0.97), and triglycerides (TAF:
16 mg per dL, TDF: 10 mg per dL; p = 0.90) (Fig. 1).
Baseline levels of biomarkers of immune activation and inﬂam-
mation were similar by treatment arm, and there were no differ-
ences between treatment groups at weeks 12, 24, or 48 (p N 0.05,Fig. 1. Fasting lipids at baseline and week 48. P-values calculated using Wilcoxon rSupplementary Table 1) for any of the markers, except for IL-6 at
week 12 only (median, TAF: 1.4 pg per mL, TDF: 1.1 pg per mL;
p = 0.012). In both arms, biomarkers of systemic inﬂammation de-
clined after ART initiation, with statistically signiﬁcant declines (as
percentage change) from baseline by week 12 for D-dimer, sCD163,
and sTNFR-1 and for IL-6 by week 24 (Fig. 2, Supplementary Table
1). We did not observe a statistically signiﬁcant decrease in hsCRP
in either arm by 48 weeks of ART; there was a trend toward decline
in sCD14 (p=0.061). At baseline, for participants in both arms com-
bined, the median Lp-PLA2 level was b200 ng per mL (median [Q1,
Q3] 196 [159, 23] ng per mL), indicating a low risk of cardiovascular
event (Packard et al., 2000; Koenig, 2006; U.S. Food and Drug
Administration, 2014). The proportion of participants with Lp-LA2
levels b200 ng per mL did not change through week 48 (p =
0.250) (Supplementary Table 2). At baseline, the overall median
hsCRP level was b3000 mg per L, also indicating a low risk for a car-
diovascular event (Ridker, 2016). The proportion of participants
with hsCRP levels b3000 mg per L similarly did not change through
week 48 (p = 0.586). Stratifying by baseline HIV-1 RNA category
(≤100,000 vs N100,000 copies per mL), we also did not ﬁnd signiﬁ-
cant differences in the percent changes in any biomarkers between
the TAF and TDF arms at any time point. For participants in each
arm and overall, we generally observed a statistically greater decline
in biomarkers for those with higher baseline HIV-1 RNA (N100,000
copies per mL) compared with those with lower baseline HIV-1
RNA (≤100,000 copies per mL) (Supplementary Table 3). Compared
with those for participants with lower baseline viral load, the de-
clines in D-dimer, sCD14, sCD163, and sTNF-R1 were greater for
those with higher viral load at baseline at all timepoints; in IL-6 at
weeks 24 and 48; and in hsCRP at week 24. We saw increases in
Lp-PLA2 in the lower baseline viral load group at week 24.
Since there was no difference between the TAF and TDF arms, we
evaluated equivalence between the TAF and TDF arms usingmultiple
statistical approaches. First, we assessed equivalence using the two
one-sided test (TOST) (Fig. 3). All biomarker percent changes were
equivalent between arms by TOST except hsCRP. The 90% CI of ratios
between two arms were within 80% to 125% for all biomarkers, ex-
cept for hsCRP, which had wider 90% CI with a ratio of 105.3%
(90%CI: 80.7%, 137.4%) when not adjusting for other covariates and
100.8% (90%CI: 76.4%, 132.9%) when adjusting for other covariates.
We then conﬁrmed the equivalence ﬁnding by TOST by using MMR
and Wilks's lambda test (p = 0.997); biomarker percent changes at
week 48 were equivalent between arms. Lastly, we used Random
Forest (ROC area under curve [AUC]), which demonstrated that
there was no differentiation between arms in any biomarker percent
changes at week 48 (Fig. 4). The AUC of ROC curve was 0.49 (95%CI:ank-sum test for treatment comparison of change from baseline at Week 48.
Fig. 2. Percent changes in markers of inﬂammation and immune activation. Plasma samples were thawed and levels of A) soluble CD14 (sCD14), soluble CD163 (sCD163), B) C reactive
protein (hsCRP), tumor necrosis factor receptor type 1 (TNFr-I), D-dimer, interleukin-6 (IL-6) and C) lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured by ELISA.
Differences in percent changes were assessed by Wilcoxon rank-sum test.
324 N.T. Funderburg et al. / EBioMedicine 13 (2016) 321–3270.41, 0.57), and variable importance scores were b0.5% for all
biomarkers.
4. Discussion
Initiation of ART has increased dramatically the expected lifespans of
persons living with HIV; yet in spite of reducing viral replication below
the limits of detection by standard clinical assays, residual chronicFig. 3. Changes in levels of biomarkers: equivalence by two one-sided test. Using TOST, equivale
ratio of treatment 1/treatment 2 is contained within a range around 100%, such as (80%–125%immune activation and systemic inﬂammation often persist (Deeks et
al., 2013, Hunt et al., 2014, and Lederman et al., 2013, Günthard et al.,
2016, European AIDS Clinical Society, EACS, 2015). As new ART drugs
become available, clinicians and patients may decide whether they
wish to change the current ART regimen. The decision to switch a viro-
logically suppressive regimen has been determined by patient tolerabil-
ity, pill burden/dosing frequency, and drug-associated toxicities (Panel
on Antiretroviral Guidelines for Adults and Adolescents, 2015). Asnce is established atα signiﬁcance level if a (1–2α) ∗ 100% conﬁdence interval (CI) for the
).
Fig. 4. Changes in levels of biomarkers: equivalence by Random Forest. Machine learning algorithm Random Forest with receiver operating characteristic (ROC) curve and variable
importance was used to assess the biomarkers' ability to differentiate between arms (Breiman, 2001). BL, baseline; Hb, hemoglobin; CLcr, creatinine clearance.
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cians and patients may wish to consider the role or association of resid-
ual immune activation and chronic inﬂammation and the association
with non-AIDS related (e.g. non-infectious, cardiovascular) morbidity
and mortality. Several contributors to chronic immune activation in
ART-treated HIV infection have been identiﬁed, including microbial
translocation, dysbiosis, coinfections, and low level viral replication
(Lederman et al., 2013). In this substudy, we compared the effects of
48 weeks of TAF versus TDF on markers of inﬂammation and immune
activation that have been associated with all-cause mortality and car-
diovascular event risk in this population (Hunt et al., 2014; Sandler et
al., 2011; Longenecker et al., 2014; Kalayjian et al., 2010; Kuller et al.,
2008; Duprez et al., 2012; Burdo et al., 2011). We hypothesized that
the declines in immune activation would be comparable given equiva-
lent virologic suppression in both arms. We report that after initiation
of ART regimens containing either TAF or TDF, therewere equivalent de-
clines in biomarkers of monocyte activation and systemic inﬂammation
over 48weeks of treatment. As expected given the results from the par-
ent study (Sax et al., 2015), substudy participants in both arms had
rapid and sustained virologic suppression and signiﬁcant increases in
CD4+ cell counts. Within both arms, we report signiﬁcant reductions
in levels of IL-6, D-dimer, sCD163, and sTNFR-1 by week 24; these de-
creases were sustained through week 48. Median levels of sCD14, a
monocyte activation marker, declined from baseline by 5.7% by week
48, which trended toward signiﬁcance (p=0.061). Somewhat surpris-
ingly, we did not ﬁnd statistically signiﬁcant reductions in plasma levels
of Lp-PLA2, a marker of vascular inﬂammation, at any time during the
study. In fact, the proportion of participants with Lp-PLA2 (as measured
bymass in our study) b200 ng per mL (the threshold for predicting car-
diovascular events) remained unchanged throughweek 48 (p=0.250).
Of note, in a subanalysis of the JUPITER study in non-HIV infected indi-
viduals, among participants allocated to placebo, increasing quartiles of
Lp-PLA2 activity (p=0.04) but not Lp-PLA2mass (p=0.92) were asso-
ciated with incident cardiovascular events after adjustment for LDL-C
and conventional risk factors (Ridker et al., 2012).
Based on the less than expected changes in sCD14 and Lp-PLA2 in
both arms, in spite of virologic control, wewanted to investigate chang-
es in lipid levels as a potential contributor to immune activation in this
study. At weeks 24 and 48, there were small, statistically signiﬁcant dif-
ferences in increases in total cholesterol, LDL cholesterol, and HDL cho-
lesterol for participants receiving TAF compared with those receiving
TDF, but no difference in the TC:HDL ratio, which is associated with car-
diovascular risk (Deeks et al., 2013;Wilson et al., 1998;D'Agostino et al.,2008; Goff et al., 2014). These ﬁndings are consistent with what has
been seen in other TAF vs TDF studies (Sax et al., 2015; Mills et al.,
2015; Wohl et al., 2016) and are thought to be due to greater plasma
TFV concentrations with TDF (Wohl et al., 2016; Tungsiripat et al.,
2010; Santos et al., 2015; Mulligan et al., 2013; Behrens et al., 2012;
Patel et al., 2014). Traditional lipid panels may underestimate cardio-
vascular risk in HIV-infected individuals, (Munger et al., 2015) and
there is growing appreciation that pro-inﬂammatory lipids may con-
tribute to immune activation in persons infectedwithHIV, including ox-
idized LDL, as levels of oxidized LDL have been associated with levels of
sCD14 in this population (Zidar et al., 2015; Hileman et al., 2016; Nou et
al., 2016). The basic lipid assessment performed in this substudy may
not be sufﬁcient to entirely capture changes in pro-inﬂammatory lipid
subspecies and their contribution to persistent immune activation. In
addition to the lack of change in the TC: HDL ratio, it is also reassuring,
however, that there were no differences between the TAF arm and the
TDF arm in Lp-PLA2 or hsCRP, indicating that the modest increases in
lipid levels in the TAF arm are likely not associated with increased car-
diovascular risk.
Limitations of the present analysis include that it was a post-hoc
substudy and may not have been appropriately powered to be able to
see differences between arms, and that we did not adjust for multiple
comparisons conducted. Another potential limitation of this study is
the lack of single copy assay measurement of viral replication or mea-
surement of HIV-1 replication in the tissues. Based on the higher intra-
cellular concentrations of TFV associated with TAF, a more sensitive
assay may have identiﬁed a differential decline in viral replication be-
tween the two arms; however, as both TAF and TDF were given with
the highly effective boosted integrase regimens, it may not be possible
to have seen this effect, even with a more sensitive assay. Indeed,
when using an HIV-1 RNA lower limit of detection of b20 copies/mL
atWeek 48, no differences in the rate of viral suppression was seen be-
tween the two treatment arms (Sax et al., 2015). Also, as there are likely
several contributors of immune activation and inﬂammation in ART-
treated HIV infection, the plasma based assays we used to measure
changes in immune activation indices may not be sensitive enough to
detect subtle changes associatedwithmodulation of any of these poten-
tial drivers of activation, including viral replication on single cell level.
We report that after initiation of ART, regimens containing either TAF
or TDF have equivalent reductions in markers of immune activation
and inﬂammation in persons living with HIV. This is a key ﬁnding, as
HIV-infected individuals are living longer, experiencing a greater cumu-
lative exposure to ART, and are at a greater risk for treatment-associated
326 N.T. Funderburg et al. / EBioMedicine 13 (2016) 321–327toxicities. Treatment with a TAF-based therapy, compared to one con-
taining TDF, has been associated with smaller declines in bone mineral
density and decreased renal toxicity (Sax et al., 2015).
5. Conclusions
Treatment with TAF, compared to TDF, yields equivalent improve-
ments in immune health and inﬂammatory indices, with decreased
bone and renal toxicity. Beyond durable suppression of HIV viremia,
treatment strategies should seek to optimize viral suppressionwhile re-
ducing residual immune activation and inﬂammation, which are in-
creasingly associated with the clinical events that now contribute
substantially to the long-termmorbidity andmortality of persons living
with HIV on lifelong therapy.
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